CytoMed Therapeutics Ltd (GDTC) stock
Close on Nov 13, 2026Market cap $9.81MP/E –Yield –
CytoMed Therapeutics Ltd grew revenue 366.7% to 324.39K SGD over fiscal 2025. Free cash flow was -4.34M SGD. At the latest close the market valued the company at 12.58M SGD.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- 12.58M SGD
- P/E ratio
- –
- Price to sales
- 38.77
- Price to book
- 1.92
- Dividend yield
- –
- Free cash flow yield
- -34.47%
Fundamentals
- Revenue
- 324.39K SGD
- Net income
- -3.98M SGD
- EPS, diluted
- -0.34 SGD
- Free cash flow
- -4.34M SGD
Trading
- Previous close
- $0.84
- Open
- $0.80
- Day's range
- $0.78 – $0.83
- Volume
- 9,291
- Average volume (20 days)
- 12,479
- Beta (5 years)
- 0.26
- RSI (14 days)
- 40.4
- Volatility (1 year)
- 91.3%
- Relative volume
- 0.15×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | GDTC | S&P 500 | Difference | GDTC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.7% | -3.0% | −1.6 pts | ||
| 3 months | -1.9% | -2.8% | +0.9 pts | ||
| Year to date | -37.9% | +11.5% | −49.4 pts | ||
| 1 year | -56.8% | +13.5% | −70.3 pts | ||
| 3 years | -79.4% | +77.7% | −157.1 pts | -41.0% | +21.1% |
Seven years at a glance
Fiscal years 2019 to 2025, SGD
Revenue
Net income
EPS, diluted
Free cash flow
Press releases
Releases CytoMed Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About CytoMed Therapeutics
Pharmaceutical Preparations
CytoMed Therapeutics Limited is a biopharmaceutical company focused on developing cell-based immunotherapies and related healthcare solutions. The company operates primarily through two segments: immune cell therapy and umbilical cord blood unit (CBU) banking services alongside related therapeutic applications. Through its subsidiaries, it engages in research, development, and provision of specialized cellular products, intellectual property licensing, and depository services for biological materials to serve clinical and therapeutic healthcare clients.
Company profile, executives and historyCytoMed Therapeutics stock: common questions
What is CytoMed Therapeutics's stock price?
GDTC closed at $0.83 on Nov 13, 2026, down 1.74% on the day.
What is CytoMed Therapeutics's market cap?
CytoMed Therapeutics was worth $9.81M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is GDTC's P/E ratio?
CytoMed Therapeutics lost money over fiscal 2025 (diluted EPS -0.34 SGD), so it has no meaningful P/E ratio.
How much revenue does CytoMed Therapeutics make?
CytoMed Therapeutics reported revenue of 324.39K SGD for fiscal 2025, up 366.7% from a year earlier.
Does CytoMed Therapeutics pay a dividend?
No. CytoMed Therapeutics has not paid a cash dividend over the last twelve months.
How has GDTC stock performed over the past year?
Including dividends, GDTC returned -56.8% over the past year, against +13.5% for the S&P 500.
Who are CytoMed Therapeutics's competitors?
Companies most similar to CytoMed Therapeutics by business, industry and size include XTLB, RGBP, ALLR, CANF, SCNX.
See a number that looks wrong?